NCT03642145View on ClinicalTrials.gov

A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)

PHASE3WithdrawnINTERVENTIONAL

0

Timeline

Start Date

October 31, 2018

Primary Completion Date

July 31, 2021

Study Completion Date

July 31, 2021

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG

Deflazacort

Deflazacort tablets will be administered as per schedule and dose specified in respective arms.

Sponsors

Lead Sponsor

PTC Therapeutics

All Listed Sponsors

lead

PTC Therapeutics

INDUSTRY

NCT03642145 - A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD) | Biotech Hunter | Biotech Hunter